[Inhibitory effect of adenovirus-mediated D2S gene plus bromocriptine therapy on primary cultures of human

Zhen-kun Xiong1, Wei-qiang Li, Jie Liu

  • 1Department of Neurosurgery, First Affiliated Hospital, Wenzhou Medical College, China.

Zhonghua Yi Xue Za Zhi
|January 8, 2013
PubMed
Abstract

Insights

Combined therapy using adenovirus-mediated dopamine 2 receptor short isoform (D2S) gene and bromocriptine effectively induces non-functioning pituitary adenoma (NFPA) cell apoptosis. This approach enhances NFPA sensitivity to dopamine agonists.

Area of Science:

  • Endocrinology
  • Molecular Biology
  • Oncology

Context:

  • Non-functioning pituitary adenomas (NFPAs) represent a significant portion of pituitary tumors.
  • Current treatment options for NFPAs have limitations, necessitating novel therapeutic strategies.
  • Understanding the molecular mechanisms underlying NFPA growth is crucial for developing targeted therapies.

Purpose:

  • To investigate the synergistic inhibitory effect of adenovirus-mediated dopamine 2 receptor short isoform (D2S) gene delivery combined with bromocriptine on NFPA cells in vitro.
  • To evaluate the induction of apoptosis and changes in cell viability in NFPA cells following this combined treatment.

Summary:

  • Adenovirus carrying the D2S gene was used to transfect NFPA cells, with successful transfection confirmed by immunofluorescence.
  • Bromocriptine treatment was administered to D2S-transfected NFPA cells, and cell apoptosis was assessed using the CCK-8 assay.
  • The combination of D2S gene transfection and bromocriptine significantly reduced NFPA cell survival to (40 ± 5)% compared to control and EGFP groups.

Impact:

  • This study demonstrates that the combined therapy effectively induces apoptosis in primary cultured NFPA cells.
  • The findings suggest that this combination therapy increases the sensitivity of NFPAs to dopamine agonists.
  • This research offers a potential novel therapeutic approach for managing non-functioning pituitary adenomas.